Indivi is an ISO 13485 and ISO 27001-certified TechBio company headquartered in Basel (Switzerland) and developing future-proof functional biomarkers derived from DHT tools measuring key disability concepts of importance for drug development trials in neuroscience therapeutic areas, e.g. multiple sclerosis, Parkinson's disease and other alpha-synucleinopathies, Alzheimer's disease and related dementias, muscular dystrophies and neuromuscular disorders.